

09857869

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul22ebb

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAOLD' AT 16:30:59 ON 18 JUN 2002  
FILE 'CAOLD' ENTERED AT 16:30:59 ON 18 JUN 2002  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.90	397.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-15.49

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.90	397.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-15.49

FILE 'CAPLUS' ENTERED AT 16:31:09 ON 18 JUN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jun 2002 VOL 136 ISS 25  
FILE LAST UPDATED: 17 Jun 2002 (20020617/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

09857869

(FILE 'HOME' ENTERED AT 16:15:40 ON 18 JUN 2002)

FILE 'REGISTRY' ENTERED AT 16:15:47 ON 18 JUN 2002

L1 STRUCTURE UPLOADED

L2 7 S L1

L3 779 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:17:53 ON 18 JUN 2002

L4 25 S L3 *Saved as Panda/A*

FILE 'CAOLD' ENTERED AT 16:23:00 ON 18 JUN 2002

L5 0 S L3

FILE 'CAPLUS' ENTERED AT 16:24:51 ON 18 JUN 2002

FILE 'CAOLD' ENTERED AT 16:25:15 ON 18 JUN 2002

FILE 'CAPLUS' ENTERED AT 16:25:49 ON 18 JUN 2002

FILE 'CAOLD' ENTERED AT 16:26:04 ON 18 JUN 2002

FILE 'CAPLUS' ENTERED AT 16:31:09 ON 18 JUN 2002

=> d 14 1-25 ibib pi fhitstr hitrn

09857869

L4 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:252956 CAPLUS

DOCUMENT NUMBER: 136:273215

TITLE: Combination of an NK-3 receptor antagonist and a CNS-penetrant NK-1 receptor antagonist for treating depression and anxiety

INVENTOR(S): Lowe, John Adams, III; McLean, Stafford; Sobolov-Jaynes, Susan Beth

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 65 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	EP 1192952	A2	20020403	EP 2001-307657	20010910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2001004345	A	20020521	BR 2001-4345	20010928
PRIORITY APPLN. INFO.:				US 2000-236375P	P 20000928
OTHER SOURCE(S):	MARPAT 136:273215				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1192952	A2	20020403	EP 2001-307657	20010910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2001004345	A	20020521	BR 2001-4345	20010928
IT	<b>185108-16-1</b>				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(combination of NK3 receptor antagonist and CNS-penetrant NK1 receptor antagonist for treating depression and anxiety)				
RN	185108-16-1 CAPLUS				
CN	Piperazine, 4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)-1-[[5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]acetyl]- (9CI) (CA INDEX NAME)				



IT 185108-16-1 204058-53-7 204058-67-3  
204058-68-4 204058-69-5 204059-08-5  
204059-12-1 204059-35-8 207404-51-1  
207404-54-4 207404-58-8 207404-73-7  
207404-95-3 207405-00-3 207405-10-5  
207405-12-7 207405-13-8 207405-14-9

09857869

207405-15-0 207405-17-2 207405-18-3  
207405-19-4 207405-37-6 207405-45-6  
207405-46-7 207405-72-9 207405-73-0  
207564-69-0 220463-19-4 220463-34-3  
220463-36-5 220463-37-6 406695-08-7  
406695-20-3 406695-40-7 406695-41-8  
406695-42-9 406695-44-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination of NK3 receptor antagonist and CNS-penetrant NK1 receptor  
antagonist for treating depression and anxiety)

09857869

L4 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:923793 CAPLUS

DOCUMENT NUMBER: 136:53766

TITLE: Process for the preparation of a piperazine derivative  
as neurokinin antagonist

INVENTOR(S): Koga, Keiichi; Orii, Ryoki; Fujii, Yosuke; Goto,  
Shunsuke; Hirabayashi, Satoshi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

C.A.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096332	A1	<u>20011220</u>	WO 2001-JP4884	20010608

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2000-176210 A 20000613

OTHER SOURCE(S): CASREACT 136:53766

LATER  
priority

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 2001096332	A1	20011220	WO 2001-JP4884	20010608
----	---------------	----	----------	----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT 381223-96-7P


RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)

(process for prepn. of piperazine deriv. as neurokinin antagonist)

RN 381223-96-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3-hydroxy-4-  
methylphenyl)methyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-,  
dihydrochloride, hydrate (2:3), (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● 2 HCl

● 3/2 H<sub>2</sub>O

IT **381223-96-7P**

RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(process for prepn. of piperazine deriv. as neurokinin antagonist)

IT **277299-25-9P**

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(process for prepn. of piperazine deriv. as neurokinin antagonist)

IT **276857-18-2P**

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for prepn. of piperazine deriv. as neurokinin antagonist)

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09857869

L4 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:725653 CAPLUS

DOCUMENT NUMBER: 133:296450

TITLE: Preparation of prenyl protein transferase inhibitors and prostate specific antigen conjugates for combination treatment of prostate cancer.

INVENTOR(S): Defeo-Jones, Deborah; Jones, Raymond E.; Oliff, Allen I.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 544 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059930	A1	20001012	WO 2000-US8762	20000331
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 1999-127746P P 19990405

OTHER SOURCE(S): MARPAT 133:296450

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000059930	A1	20001012	WO 2000-US8762	20000331
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

IT 183498-91-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(prepn. of prenyl protein transferase inhibitors and prostate specific antigen conjugates for combination treatment of prostate cancer)

RN 183498-91-1 CAPLUS

CN Piperazine, 1-(1H-imidazol-4-ylmethyl)-4-(1-naphthalenylcarbonyl)-2-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869



IT 183498-91-1 301296-68-4 301296-69-5  
301296-70-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of prenyl protein transferase inhibitors and prostate specific antigen conjugates for combination treatment of prostate cancer)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



09857869

L4 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:641466 CAPLUS

DOCUMENT NUMBER: 133:350193

TITLE: Non-amide-based combinatorial libraries derived from N-BOC-iminodiacetic acid: solution-phase synthesis of piperazinone libraries with activity against LEF-1/.beta.-catenin-mediated transcription

AUTHOR(S): Boger, Dale L.; Goldberg, Joel; Satoh, Shigeki; Ambroise, Yves; Cohen, Steven B.; Vogt, Peter K.

CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA

SOURCE: Helvetica Chimica Acta (2000), 83(8), 1825-1845

CODEN: HCACAV; ISSN: 0018-019X

PUBLISHER: Verlag Helvetica Chimica Acta

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 305325-55-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of non-amide-based combinatorial libraries derived from N-BOC-iminodiacetic acid and soln.-phase synthesis of piperazinone libraries with activity against lymphoid-enhancer factor-1/.beta.-catenin-mediated transcription)

RN 305325-55-7 CAPLUS

CN Piperazinone, 1-(2-furanylmethyl)-4-(4-methoxybenzoyl)-6-(phenylmethyl)-(9CI) (CA INDEX NAME)



IT 305325-55-7P 305325-56-8P 305325-57-9P

305326-17-4P 305326-18-5P 305326-19-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of non-amide-based combinatorial libraries derived from N-BOC-iminodiacetic acid and soln.-phase synthesis of piperazinone libraries with activity against lymphoid-enhancer factor-1/.beta.-catenin-mediated transcription)

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09857869

L4 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:421138 CAPLUS

DOCUMENT NUMBER: 133:58814

TITLE: Preparation of piperazines for treating or preventing tachykinin-mediated diseases

INVENTOR(S): Take, Kazuhiko; Konishi, Nobukiyo; Shigenaga, Shinji; Kayakiri, Natsuko; Azami, Hidenori; Eikyu, Yoshiteru; Nakai, Kazuo; Ishida, Junya; Morita, Masataka

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 245 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

Apps, PCT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035915	A1	20000622	WO 1999-JP6943	19991210
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1140924	A1	20011010	EP 1999-959751	19991210
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRIORITY APPLN. INFO.:			AU 1998-7706	A 19981214
			AU 1999-3568	A 19991021
			WO 1999-JP6943	W 19991210

OTHER SOURCE(S): MARPAT 133:58814

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000035915	A1	20000622	WO 1999-JP6943	19991210
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1140924	A1	20011010	EP 1999-959751	19991210
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

IT 276857-11-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of piperazines for treating or preventing tachykinin-mediated diseases)

RN 276857-11-5 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-[(2-methoxyethoxy)methoxy]-4-methylphenyl)methyl]-4-[2-[(3R)-3-(methoxymethyl)-4-morpholinyl]ethyl]- (9CI) (CA INDEX NAME)

09857869

Absolute stereochemistry.



IT 276857-11-5P 276857-18-2P 276857-20-6P  
276858-29-8P 276858-67-4P 276858-84-5P  
276858-90-3P 276859-60-0P 276859-61-1P  
276859-62-2P 276859-63-3P 276859-64-4P  
276859-70-2P 276859-85-9P 276860-42-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of piperazines for treating or preventing tachykinin-mediated diseases)

IT 276857-12-6P 276857-13-7P 276857-14-8P  
276857-15-9P 276857-16-0P 276857-17-1P  
276857-19-3P 276857-21-7P 276857-22-8P  
276857-23-9P 276857-24-0P 276857-25-1P  
276857-26-2P 276857-27-3P 276857-28-4P  
276857-29-5P 276857-30-8P 276857-31-9P  
276857-32-0P 276857-33-1P 276857-34-2P  
276857-35-3P 276857-36-4P 276857-37-5P  
276857-38-6P 276857-39-7P 276857-40-0P  
276857-41-1P 276857-42-2P 276857-43-3P  
276857-44-4P 276857-45-5P 276857-46-6P  
276857-47-7P 276857-48-8P 276857-49-9P  
276857-50-2P 276857-51-3P 276857-52-4P  
276857-53-5P 276857-54-6P 276857-55-7P  
276857-56-8P 276857-57-9P 276857-58-0P  
276857-59-1P 276857-60-4P 276857-61-5P  
276857-62-6P 276857-63-7P 276857-64-8P  
276857-65-9P 276857-66-0P 276857-67-1P  
276857-68-2P 276857-69-3P 276857-70-6P  
276857-71-7P 276857-72-8P 276857-73-9P  
276857-74-0P 276857-75-1P 276857-76-2P  
276857-77-3P 276857-78-4P 276857-79-5P  
276857-80-8P 276857-81-9P 276857-82-0P  
276857-83-1P 276857-84-2P 276857-85-3P  
276857-86-4P 276857-87-5P 276857-88-6P  
276857-89-7P 276857-90-0P 276857-91-1P  
276857-92-2P 276857-93-3P 276857-94-4P  
276857-95-5P 276857-96-6P 276857-97-7P  
276857-98-8P 276857-99-9P 276858-00-5P

276858-01-6P 276858-02-7P 276858-03-8P  
 276858-04-9P 276858-05-0P 276858-06-1P  
 276858-07-2P 276858-08-3P 276858-09-4P  
 276858-10-7P 276858-11-8P 276858-21-0P  
 276858-22-1P 276858-23-2P 276858-24-3P  
 276858-25-4P 276858-26-5P 276858-27-6P  
 276858-28-7P 276858-30-1P 276858-31-2P  
 276858-32-3P 276858-33-4P 276858-34-5P  
 276858-35-6P 276858-36-7P 276858-37-8P  
 276858-38-9P 276858-39-0P 276858-40-3P  
 276858-41-4P 276858-42-5P 276858-43-6P  
 276858-44-7P 276858-45-8P 276858-46-9P  
 276858-47-0P 276858-48-1P 276858-49-2P  
 276858-50-5P 276858-51-6P 276858-52-7P  
 276858-53-8P 276858-54-9P 276858-55-0P  
 276858-56-1P 276858-57-2P 276858-58-3P  
 276858-59-4P 276858-60-7P 276858-61-8P  
 276858-62-9P 276858-63-0P 276858-64-1P  
 276858-65-2P 276858-66-3P 276858-68-5P  
 276858-69-6P 276858-70-9P 276858-71-0P  
 276858-72-1P 276858-73-2P 276858-74-3P  
 276858-75-4P 276858-76-5P 276858-77-6P  
 276858-78-7P 276858-79-8P 276858-80-1P  
 276858-81-2P 276858-82-3P 276858-83-4P  
 276858-85-6P 276858-86-7P 276858-87-8P  
 276858-88-9P 276858-89-0P 276858-91-4P  
 276858-92-5P 276858-93-6P 276858-94-7P  
 276858-95-8P 276858-96-9P 276858-97-0P  
 276858-98-1P 276858-99-2P 276859-00-8P  
 276859-01-9P 276859-02-0P 276859-03-1P  
 276859-04-2P 276859-05-3P 276859-06-4P  
 276859-07-5P 276859-08-6P 276859-09-7P  
 276859-10-0P 276859-11-1P 276859-12-2P  
 276859-13-3P 276859-14-4P 276859-15-5P  
 276859-16-6P 276859-17-7P 276859-18-8P  
 276859-19-9P 276859-20-2P 276859-21-3P  
 276859-22-4P 276859-23-5P 276859-24-6P  
 276859-25-7P 276859-26-8P 276859-27-9P  
 276859-28-0P 276859-29-1P 276859-30-4P  
 276859-31-5P 276859-32-6P 276859-33-7P  
 276859-34-8P 276859-35-9P 276859-36-0P  
 276859-37-1P 276859-38-2P 276859-39-3P  
 276859-40-6P 276859-41-7P 276859-42-8P  
 276859-43-9P 276859-44-0P 276859-45-1P  
 276859-46-2P 276859-47-3P 276859-48-4P  
 276859-49-5P 276859-50-8P 276859-51-9P  
 276859-52-0P 276859-53-1P 276859-54-2P  
 276859-55-3P 276859-56-4P 276859-57-5P  
 276859-58-6P 276859-59-7P 276859-65-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of piperazines for treating or preventing tachykinin-mediated diseases)

IT 276859-66-6P 276859-67-7P 276859-68-8P  
 276859-69-9P 276859-71-3P 276859-72-4P  
 276859-73-5P 276859-74-6P 276859-75-7P  
 276859-76-8P 276859-77-9P 276859-78-0P  
 276859-79-1P 276859-80-4P 276859-81-5P  
 276859-82-6P 276859-83-7P 276859-84-8P  
 276859-86-0P 276859-87-1P 276859-88-2P

09857869

276859-89-3P 276859-90-6P 276859-91-7P  
276859-92-8P 276859-93-9P 276859-94-0P  
276859-95-1P 276859-96-2P 276859-97-3P  
276859-98-4P 276859-99-5P 276860-00-5P  
276860-01-6P 276860-02-7P 276860-03-8P  
276860-04-9P 276860-05-0P 276860-06-1P  
276860-07-2P 276860-08-3P 276860-09-4P  
276860-10-7P 276860-11-8P 276860-12-9P  
276860-13-0P 276860-14-1P 276860-15-2P  
276860-16-3P 276860-17-4P 276860-18-5P  
276860-19-6P 276860-20-9P 276860-21-0P  
276860-22-1P 276860-23-2P 276860-24-3P  
276860-25-4P 276860-26-5P 276860-27-6P  
276860-28-7P 276860-29-8P 276860-30-1P  
276860-31-2P 276860-32-3P 276860-33-4P  
276860-34-5P 276860-35-6P 276860-36-7P  
276860-37-8P 276860-38-9P 276860-39-0P  
276860-40-3P 276860-41-4P 276860-43-6P  
276860-44-7P 276860-45-8P 276860-46-9P  
276860-47-0P 276860-48-1P 276860-49-2P  
276861-77-9P 276862-96-5P 277299-25-9P  
277299-26-0P 277300-74-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazines for treating or preventing tachykinin-mediated diseases)

IT 276862-92-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of piperazines for treating or preventing tachykinin-mediated diseases)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09857869

L4 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:670114 CAPLUS

DOCUMENT NUMBER: 131:286538

TITLE: Preparation of 1,4-diacyl piperazines and analogs as neurokinin antagonists

INVENTOR(S): Blythin, David J.; Chen, Xiao; Friary, Richard J.; McCormick, Kevin D.; Piwinski, John J.; Shih, Neng-yang; Shue, Ho-jane

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S., 85 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5968929	A	19991019	US 1997-958896	19971028
US 6051575	A	20000418	US 1999-313150	19990517

PRIORITY APPLN. INFO.: US 1996-29813P P 19961030  
US 1997-958896 A3 19971028

OTHER SOURCE(S): MARPAT 131:286538

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5968929	A	19991019	US 1997-958896	19971028
US 6051575	A	20000418	US 1999-313150	19990517


IT **207404-52-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 1,4-diacyl piperazines and analogs as neurokinin antagonists)

RN 207404-52-2 CAPLUS

CN Piperazine, 1-[3-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-oxopropyl]-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-, dihydrochloride, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



09857869

IT 207404-52-2P 207404-54-4P 207404-64-6P  
207404-65-7P 207404-66-8P 207404-67-9P  
207404-68-0P 207404-69-1P 207404-70-4P  
207404-71-5P 207404-72-6P 207404-93-1P  
207404-95-3P 207404-96-4P 207404-97-5P  
207404-98-6P 207404-99-7P 207405-00-3P  
207405-01-4P 207405-02-5P 207405-03-6P  
207405-04-7P 207405-05-8P 207405-06-9P  
207405-07-0P 207405-08-1P 207405-09-2P  
207405-10-5P 207405-11-6P 207405-12-7P  
207405-13-8P 207405-14-9P 207405-15-0P  
207405-16-1P 207405-17-2P 207405-18-3P  
207405-19-4P 207405-37-6P 207405-46-7P  
207405-47-8P 207405-48-9P 207405-49-0P  
207405-50-3P 207405-51-4P 207405-52-5P  
207405-53-6P 207405-54-7P 207405-55-8P  
207405-56-9P 207405-72-9P 207405-73-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 1,4-diacyl piperazines and analogs as neurokinin antagonists)

IT 207404-51-1P 207404-53-3P 207404-55-5P  
207404-56-6P 207404-57-7P 207404-58-8P  
207404-59-9P 207404-60-2P 207404-61-3P  
207404-62-4P 207404-63-5P 207404-73-7P  
207404-94-2P 207405-45-6P 207564-69-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 1,4-diacyl piperazines and analogs as neurokinin antagonists)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09857869

L4 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:468588 CAPLUS

DOCUMENT NUMBER: 131:116242

TITLE: Preparation of 2-(aminoalkanoyl)-4-benzoyl-2-phenylpiperazine derivatives as neurokinin antagonists

INVENTOR(S): Shue, Ho-Jane; Shih, Neng-Yang; Blythin, David J.; Chen, Xiao; Piwinski, John J.; McCormick, Kevin D.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9936424	A1	19990722	WO 1999-US46	19990111
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
ZA 9900171	A	19990712	ZA 1999-171	19990111
CA 2317760	AA	19990722	CA 1999-2317760	19990111
AU 9921013	A1	19990802	AU 1999-21013	19990111
EP 1047698	A1	20001102	EP 1999-901277	19990111
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
JP 2002509151	T2	20020326	JP 2000-540140	19990111
PRIORITY APPLN. INFO.:			US 1998-6942	A2 19980114
			WO 1999-US46	W 19990111

OTHER SOURCE(S): MARPAT 131:116242

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9936424	A1	19990722	WO 1999-US46	19990111
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
ZA 9900171	A	19990712	ZA 1999-171	19990111
CA 2317760	AA	19990722	CA 1999-2317760	19990111
AU 9921013	A1	19990802	AU 1999-21013	19990111
EP 1047698	A1	20001102	EP 1999-901277	19990111
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
JP 2002509151	T2	20020326	JP 2000-540140	19990111

IT 207404-51-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of (aminoalkanoyl)benzoylphenylpiperazine derivs. as neurokinin antagonists for treatment of diseases)

RN 207404-51-1 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[3-[(2R)-2-(3,4-



09857869

dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-3-oxopropyl]-,  
1,1-dimethylethyl ester, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 207404-51-1P 207404-52-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. of (aminoalkanoyl)benzoylphenylpiperazine derivs. as neurokinin  
antagonists for treatment of diseases)

IT 207405-47-8P 207405-48-9P 207405-49-0P

232269-77-1P 232269-79-3P 232269-80-6P

232269-81-7P 232269-82-8P 232269-83-9P

232269-84-0P 232269-85-1P 232269-86-2P

232269-87-3P 232269-88-4P 232269-89-5P

232269-90-8P 232269-91-9P 232269-92-0P

232269-93-1P 232269-94-2P 232269-96-4P

232269-97-5P 232269-98-6P 232269-99-7P

232270-00-7P 232270-01-8P 232270-02-9P

232270-03-0P 232270-04-1P 232270-05-2P

232270-06-3P 232270-07-4P 232270-08-5P

232270-09-6P 232270-10-9P 232270-11-0P

232270-12-1P 232270-13-2P 232270-15-4P

232270-16-5P 232270-26-7P 232270-28-9P

232270-30-3P 232270-32-5P 232270-33-6P

232270-34-7P 232270-36-9P 232270-37-0P

232270-38-1P 232270-39-2P 232270-40-5P

232270-41-6P 232270-42-7P 232270-43-8P

232270-44-9P 232270-45-0P 232270-46-1P

232270-47-2P 232270-48-3P 232270-49-4P

232270-50-7P 232270-51-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)

(prepn. of (aminoalkanoyl)benzoylphenylpiperazine derivs. as neurokinin  
antagonists for treatment of diseases)

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09857869

L4 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:231218 CAPLUS  
DOCUMENT NUMBER: 130:252385  
TITLE: Preparation of piperazine derivatives as neurokinin antagonists  
INVENTOR(S): Shue, Ho-Jane; Shih, Neng-Yang; Blythin, David J.; Chen, Xiao; Piwinski, John J.; McCormick, Kevin D.  
PATENT ASSIGNEE(S): Schering Corporation, USA  
SOURCE: U.S., 47 pp., Cont.-in-part of U.S. 5,795,894.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

*Saw all Nits (IV.P)*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5892039	A	19990406	US 1996-706016	19960830
WO 9634864	A1	19961107	WO 1996-US5660	19960501
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5795894	A	19980818	US 1996-663880	19960614
WO 9808826	A1	19980305	WO 1997-US14709	19970828
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9740800	A1	19980319	AU 1997-40800	19970828
EP 927170	A1	19990707	EP 1997-938490	19970828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
CN 1234026	A	19991103	CN 1997-199121	19970828
JP 2000516956	T2	20001219	JP 1998-511732	19970828

PRIORITY APPLN. INFO.:

WO 1996-US5660	W	19960501
US 1996-663880	A2	19960614
US 1995-432739	A	19950502
US 1995-3084P	P	19950831
US 1996-706016	A	19960830
WO 1997-US14709	A	19970828

OTHER SOURCE(S): MARPAT 130:252385

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5892039	A	19990406	US 1996-706016	19960830
WO 9634864	A1	19961107	WO 1996-US5660	19960501
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5795894	A	19980818	US 1996-663880	19960614
WO 9808826	A1	19980305	WO 1997-US14709	19970828

09857869

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9740800 A1 19980319 AU 1997-40800 19970828

EP 927170 A1 19990707 EP 1997-938490 19970828

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO

CN 1234026 A 19991103 CN 1997-199121 19970828


JP 2000516956 T2 20001219 JP 1998-511732 19970828

IT **204059-14-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Rlprepn. of piperazine derivs. as NK1 and NK2 antagonists)

RN 204059-14-3 CAPLUS

CN Piperazine, 2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[3-[4-(2-furanylmethyl)-1-piperidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



IT **204059-14-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Rlprepn. of piperazine derivs. as NK1 and NK2 antagonists)

IT **204058-53-7P 204058-54-8P 204058-55-9P**

**204058-56-0P 204058-57-1P 204058-58-2P**

**204058-59-3P 204058-60-6P 204058-61-7P**

**204058-62-8P 204058-64-0P 204058-65-1P**

**204058-66-2P 204058-67-3P 204058-68-4P**

**204058-69-5P 204058-74-2P 204058-75-3P**

**204058-76-4P 204058-77-5P 204058-98-0P**

**204059-03-0P 204059-08-5P 204059-15-4P**

**204059-16-5P 204059-17-6P 204059-22-3P**

**204059-23-4P 204059-24-5P 204059-25-6P**

**204059-35-8P 221685-04-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazine derivs. as NK1 and NK2 antagonists)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09857869

L4 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:104517 CAPLUS

DOCUMENT NUMBER: 130:168394

TITLE: Preparation of 1,4-diacylpiperazines as neurokinin antagonists.

INVENTOR(S): Shue, Ho-Jane; Shih, Neng-Yang; Blythin, David J.; Chen, Xiao; Piwinski, John J.; McCormick, Kevin D.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S., 57 pp., Cont.-in-part of U.S. Ser. No. 663,880.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5869488	A	19990209	US 1996-703154	19960829
US 5795894	A	19980818	US 1996-663880	19960614
PRIORITY APPLN. INFO.:			US 1996-663880 A2	19960614
			US 1995-432739 A2	19950502

OTHER SOURCE(S): MARPAT 130:168394

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5869488	A	19990209	US 1996-703154	19960829
US 5795894	A	19980818	US 1996-663880	19960614


IT **220463-19-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 1,4-diacylpiperazines as neurokinin antagonists)

RN 220463-19-4 CAPLUS

CN Piperazine, 2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[1-oxo-3-[(1S,4S)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT **220463-19-4P 220463-33-2P 220463-34-3P**

**220463-35-4P 220463-36-5P 220463-37-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 1,4-diacylpiperazines as neurokinin antagonists)

09857869

REFERENCE COUNT:

26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09857869

L4 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:34471 CAPLUS

DOCUMENT NUMBER: 130:95565

TITLE: Preparation of 1-aryl(carbonyl)-2-piperazinones and

analogues as farnesyl protein transferase inhibitors

INVENTOR(S): Anthony, Neville J.; Ciccarone, Terrence M.; Dinsmore, Christopher J.; Gomez, Robert P.; Williams, Theresa M.; Hartman, George D.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: U.S., 68 pp., Cont.-in-part of U.S. Ser. No. 470,690, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

*Sam Hits*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5856326	A	19990105	US 1996-600728	19960301
CA 2216707	AA	19961003	CA 1996-2216707	19960325
WO 9630343	A1	19961003	WO 1996-US4019	19960325
W:	AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, US, US, UZ, VN, AM, AZ, BY, KG			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9653223	A1	19961016	AU 1996-53223	19960325
AU 710672	B2	19990923		
EP 820445	A1	19980128	EP 1996-909851	19960325
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI			
BR 9607953	A	19980714	BR 1996-7953	19960325
CN 1195340	A	19981007	CN 1996-194206	19960325
JP 10511098	T2	19981027	JP 1996-529559	19960325
JP 3043815	B2	20000522		
ZA 9602433	A	19961002	ZA 1996-2433	19960327
NO 9704457	A	19971128	NO 1997-4457	19970926

PRIORITY APPLN. INFO.:

US 1995-412829	B2	19950329
US 1995-470690	B2	19950606
US 1996-600728	A	19960301
WO 1996-US4019	W	19960325

OTHER SOURCE(S): MARPAT 130:95565

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5856326	A	19990105	US 1996-600728	19960301
CA 2216707	AA	19961003	CA 1996-2216707	19960325
WO 9630343	A1	19961003	WO 1996-US4019	19960325
W:	AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, US, US, UZ, VN, AM, AZ, BY, KG			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9653223	A1	19961016	AU 1996-53223	19960325
AU 710672	B2	19990923		
EP 820445	A1	19980128	EP 1996-909851	19960325
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,			

09857869

SI, LT, LV, FI

BR 9607953	A	19980714	BR 1996-7953	19960325
CN 1195340	A	19981007	CN 1996-194206	19960325
JP 10511098	T2	19981027	JP 1996-529559	19960325
JP 3043815	B2	20000522		
ZA 9602433	A	19961002	ZA 1996-2433	19960327
NO 9704457	A	19971128	NO 1997-4457	19970926

IT **183498-92-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 1-aryl(carbonyl)-2-piperazinones and analogs as farnesyl protein transferase inhibitors)

RN 183498-92-2 CAPLUS

CN Piperazine, 1-(1H-imidazol-4-ylmethyl)-4-(1-naphthalenylcarbonyl)-2-(phenylmethyl)-, (2S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 183498-91-1

CMF C26 H26 N4 O

CDES 1:S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT **183498-92-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 1-aryl(carbonyl)-2-piperazinones and analogs as farnesyl protein transferase inhibitors)

IT **183499-83-4P**

09857869

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(prepn. of 1-aryl(carbonyl)-2-piperazinones and analogs as farnesyl  
protein transferase inhibitors)

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



09857869

L4 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:9836 CAPLUS

DOCUMENT NUMBER: 130:81525

TITLE: Preparation of aroylpiperazines as tachykinin antagonists.

INVENTOR(S): Miyake, Hiroshi; Take, Kazuhiko; Shigenaga, Shinji; Azami, Hidenori; Sasaki, Hiroshi; Eikyu, Yoshiteru; Nakai, Kazuo; Ishida, Junya; Manabe, Takashi; Konishi, Nobukiyo; Terasaka, Tadashi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 200 pp.

C.C.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

*provided*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857954	A1	19981223	WO 1998-JP2613	19980615
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9876750	A1	19990104	AU 1998-76750	19980615
AU 743723	B2	20020131		
EP 993457	A1	20000419	EP 1998-924610	19980615
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
BR 9810146	A	20000808	BR 1998-10146	19980615
JP 2002504929	T2	20020212	JP 1999-504127	19980615
ZA 9805255	A	19990106	ZA 1998-5255	19980617
PRIORITY APPLN. INFO.:			AU 1997-7359	A 19970617
			WO 1998-JP2613	W 19980615

OTHER SOURCE(S): MARPAT 130:81525

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9857954	A1	19981223	WO 1998-JP2613	19980615
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9876750	A1	19990104	AU 1998-76750	19980615
AU 743723	B2	20020131		
EP 993457	A1	20000419	EP 1998-924610	19980615
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
BR 9810146	A	20000808	BR 1998-10146	19980615
JP 2002504929	T2	20020212	JP 1999-504127	19980615
ZA 9805255	A	19990106	ZA 1998-5255	19980617

IT 218592-67-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


09857869

(prepn. of aroylpiperazines as tachykinin antagonists)

RN 218592-67-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-(1H-pyrazol-4-ylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 218592-67-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of aroylpiperazines as tachykinin antagonists)

IT 218592-28-0P 218592-30-4P 218592-36-0P  
218592-38-2P 218592-45-1P 218592-46-2P  
218592-47-3P 218592-48-4P 218592-49-5P  
218592-50-8P 218592-53-1P 218592-54-2P  
218592-55-3P 218592-56-4P 218592-58-6P  
218592-64-4P 218592-65-5P 218592-68-8P  
218592-69-9P 218592-71-3P 218592-74-6P  
218592-75-7P 218592-76-8P 218592-77-9P  
218592-78-0P 218592-79-1P 218592-84-8P  
218592-85-9P 218592-86-0P 218592-87-1P  
218592-88-2P 218592-89-3P 218592-90-6P  
218592-91-7P 218592-93-9P 218592-95-1P  
218592-97-3P 218592-99-5P 218593-00-1P  
218593-02-3P 218593-04-5P 218593-06-7P  
218593-13-6P 218593-17-0P 218593-18-1P  
218593-19-2P 218593-20-5P 218593-21-6P  
218593-22-7P 218593-23-8P 218593-24-9P  
218593-25-0P 218593-26-1P 218593-27-2P  
218593-28-3P 218593-29-4P 218593-30-7P  
218593-32-9P 218593-33-0P 218593-34-1P  
218593-35-2P 218593-37-4P 218593-39-6P  
218593-43-2P 218593-44-3P 218593-46-5P  
218593-47-6P 218593-48-7P 218593-49-8P  
218593-50-1P 218593-51-2P 218593-52-3P  
218593-53-4P 218593-56-7P 218593-57-8P  
218593-58-9P 218593-59-0P 218593-60-3P  
218593-61-4P 218593-62-5P 218593-68-1P  
218593-69-2P 218593-71-6P 218593-73-8P  
218593-75-0P 218593-77-2P 218593-80-7P  
218593-84-1P 218593-85-2P 218593-86-3P

09857869

**218593-87-4P 218593-88-5P 218593-89-6P**

**218593-91-0P 218593-92-1P 218593-93-2P**

**218785-28-5P 218785-30-9P 218785-32-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aroylpiperazines as tachykinin antagonists)

IT **218595-17-6 218785-40-1 218785-42-3**

**218785-45-6**

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of aroylpiperazines as tachykinin antagonists)

IT **192660-44-9P 218594-27-5P 218595-26-7P**

**218595-27-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of aroylpiperazines as tachykinin antagonists)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09857869

L4 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:804132 CAPLUS

DOCUMENT NUMBER: 130:33009

TITLE: A method of treating cancer using an antineoplastic agent-prenyl-protein transferase inhibitor combination, and compound preparation

INVENTOR(S): Rosen, Neal; Sepp-lorenzino, Laura; Moasser, Mark M.; Oliff, Allen I.; Gibbs, Jackson B.; Kohl, Nancy; Graham, Samuel L.; Prendergast, George C.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Sloan-Kettering Institute for Cancer Research

SOURCE: PCT Int. Appl., 379 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9854966	A1	19981210	WO 1998-US8646	19980604
W:				
AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9877957	A1	19981221	AU 1998-77957	19980604
EP 986302	A1	20000322	EP 1998-926029	19980604
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002503249	T2	20020129	JP 1999-502409	19980604
PRIORITY APPLN. INFO.:			US 1997-48736P	P 19970605
			GB 1998-1231	A 19980121
			WO 1998-US8646	W 19980604

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9854966	A1	19981210	WO 1998-US8646	19980604
W:				
AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9877957	A1	19981221	AU 1998-77957	19980604
EP 986302	A1	20000322	EP 1998-926029	19980604
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002503249	T2	20020129	JP 1999-502409	19980604

IT 183498-91-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(antineoplastic agent-prenyl-protein transferase inhibitor combination for treating cancer, and compd. prepn.)

RN 183498-91-1 CAPLUS

CN Piperazine, 1-(1H-imidazol-4-ylmethyl)-4-(1-naphthalenylcarbonyl)-2-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869



IT **183498-91-1**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antineoplastic agent-prenyl-protein transferase inhibitor combination for treating cancer, and compd. prepn.)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09857869

L4 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:677821 CAPLUS

DOCUMENT NUMBER: 129:302890

TITLE: Treatment of cancer using a combination of integrin antagonists and farnesyl protein transferase inhibitors.

INVENTOR(S): Duggan, Mark E.; Hartman, George D.; Heimbrook, David C.; Oliff, Allen I.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 422 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9844797	A1	19981015	WO 1998-US6823	19980406
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9869532	A1	19981030	AU 1998-69532	19980406
AU 724216	B2	20000914		
EP 973396	A1	20000126	EP 1998-915318	19980406
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001524079	T2	20011127	JP 1998-543013	19980406
PRIORITY APPLN. INFO.:			US 1997-41923P	P 19970407
			GB 1998-976	A 19980116
			WO 1998-US6823	W 19980406

OTHER SOURCE(S): MARPAT 129:302890

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9844797	A1	19981015	WO 1998-US6823	19980406
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9869532	A1	19981030	AU 1998-69532	19980406
AU 724216	B2	20000914		
EP 973396	A1	20000126	EP 1998-915318	19980406
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001524079	T2	20011127	JP 1998-543013	19980406

IT 183498-91-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(treatment of cancer using a combination of integrin antagonists and farnesyl protein transferase inhibitors)

RN 183498-91-1 CAPLUS

CN Piperazine, 1-(1H-imidazol-4-ylmethyl)-4-(1-naphthalenylcarbonyl)-2-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

09857869

Absolute stereochemistry.



IT **183498-91-1**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of cancer using a combination of integrin antagonists and farnesyl protein transferase inhibitors)

09857869

L4 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:564199 CAPLUS  
DOCUMENT NUMBER: 129:189341  
TITLE: Preparation of piperazines as neurokinin antagonists  
INVENTOR(S): Shue, Ho-jane; Shih, Neng-yang; Blythin, David J.;  
Chen, Xiao; Tom, Wing C.; Piwinski, John J.;  
McCormick, Kevin D.  
PATENT ASSIGNEE(S): Schering Corp., USA  
SOURCE: U.S., 92 pp., Cont.-in-part of U. S. 5,719,156.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5795894	A	19980818	US 1996-663880	19960614
US 5719156	A	19980217	US 1995-432739	19950502
US 5798359	A	19980825	US 1995-451113	19950525
CN 1189829	A	19980805	CN 1996-195171	19960501
CA 2228370	AA	19970306	CA 1996-2228370	19960829
WO 9708166	A1	19970306	WO 1996-IB1018	19960829
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9669979	A1	19970319	AU 1996-69979	19960829
AU 708834	B2	19990812		
EP 850236	A1	19980701	EP 1996-931188	19960829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI				
JP 10511105	T2	19981027	JP 1996-510069	19960829
CN 1200120	A	19981125	CN 1996-197720	19960829
US 5869488	A	19990209	US 1996-703154	19960829
BR 9610277	A	19990706	BR 1996-10277	19960829
JP 2000344766	A2	20001212	JP 2000-153870	19960829
AT 202776	E	20010715	AT 1996-931188	19960829
ES 2158345	T3	20010901	ES 1996-931188	19960829
US 5892039	A	19990406	US 1996-706016	19960830
NO 9800848	A	19980430	NO 1998-848	19980227
US 5981520	A	19991109	US 1998-99221	19980617
PRIORITY APPLN. INFO.:			US 1995-432739	A2 19950502
			US 1995-3084P	P 19950831
			WO 1996-US5660	W 19960501
			US 1996-663880	A 19960614
			JP 1997-510069	A3 19960829
			WO 1996-IB1018	W 19960829

OTHER SOURCE(S): MARPAT 129:189341

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5795894	A	19980818	US 1996-663880	19960614
US 5719156	A	19980217	US 1995-432739	19950502
US 5798359	A	19980825	US 1995-451113	19950525
CN 1189829	A	19980805	CN 1996-195171	19960501
CA 2228370	AA	19970306	CA 1996-2228370	19960829
WO 9708166	A1	19970306	WO 1996-IB1018	19960829
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS,				



09857869


JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL,  
RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG,  
KZ, MD, RU, TJ, TM  
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,  
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,  
MR, NE, SN, TD, TG  
AU 9669979 A1 19970319 AU 1996-69979 19960829  
AU 708834 B2 19990812  
EP 850236 A1 19980701 EP 1996-931188 19960829  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,  
LT, LV, FI  
JP 10511105 T2 19981027 JP 1996-510069 19960829  
CN 1200120 A 19981125 CN 1996-197720 19960829  
US 5869488 A 19990209 US 1996-703154 19960829  
BR 9610277 A 19990706 BR 1996-10277 19960829  
JP 2000344766 A2 20001212 JP 2000-153870 19960829  
AT 202776 E 20010715 AT 1996-931188 19960829  
ES 2158345 T3 20010901 ES 1996-931188 19960829  
US 5892039 A 19990406 US 1996-706016 19960830  
NO 9800848 A 19980430 NO 1998-848 19980227  
US 5981520 A 19991109 US 1998-99221 19980617

IT **185108-16-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazines as neurokinin antagonists)

RN 185108-16-1 CAPLUS

CN Piperazine, 4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)-1-[[5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]acetyl]- (9CI) (CA INDEX NAME)



IT **185108-16-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazines as neurokinin antagonists)

09857869

L4 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:479528 CAPLUS

DOCUMENT NUMBER: 129:95513

TITLE: Preparation of Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists

INVENTOR(S): McCormick, Kevin D.

PATENT ASSIGNEE(S): Schering Corp., USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828297	A1	19980702	WO 1997-US22519	19971218
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5783579	A	19980721	US 1996-771714	19961220
AU 9855202	A1	19980717	AU 1998-55202	19971218
EP 950058	A1	19991020	EP 1997-951600	19971218
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
CN 1240447	A	20000105	CN 1997-180629	19971218
JP 2001507351	T2	20010605	JP 1998-528801	19971218
PRIORITY APPLN. INFO.:			US 1996-771714 A	19961220
			WO 1997-US22519 W	19971218

OTHER SOURCE(S): CASREACT 129:95513; MARPAT 129:95513

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9828297	A1	19980702	WO 1997-US22519	19971218
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5783579	A	19980721	US 1996-771714	19961220
AU 9855202	A1	19980717	AU 1998-55202	19971218
EP 950058	A1	19991020	EP 1997-951600	19971218
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
CN 1240447	A	20000105	CN 1997-180629	19971218
JP 2001507351	T2	20010605	JP 1998-528801	19971218

IT 209747-71-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazine derivs. as neurokinin antagonists)

RN 209747-71-7 CAPLUS

CN Piperazine, 2-(3,4-dichlorophenyl)-1-[3-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]-1-oxopropyl]-4-(3,5-dimethylbenzoyl)-, (2R)- (9CI) (CA INDEX NAME)

09857869

Absolute stereochemistry.



X

IT **209747-71-7P 209747-72-8P 209747-73-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazine derivs. as neurokinin antagonists)

09857869

L4 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:293498 CAPLUS

DOCUMENT NUMBER: 129:4660

TITLE: Preparation of diacylpiperazine derivatives as neurokinin antagonists.

INVENTOR(S): Blythin, David J.; Chen, Xiao; Friary, Richard J.; McCormick, Kevin D.; Piwinski, John J.; Shih, Neng-yang; Shue, Ho-jane

PATENT ASSIGNEE(S): Schering Corp., USA

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818788	A1	19980507	WO 1997-US18986	19971028
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
ZA 9709670	A	19980428	ZA 1997-9670	19971028
AU 9749917	A1	19980522	AU 1997-49917	19971028
AU 733454	B2	20010517		
EP 937069	A1	19990825	EP 1997-912827	19971028
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
BR 9712720	A	19991026	BR 1997-12720	19971028
CN 1241187	A	20000112	CN 1997-180916	19971028
JP 2000504342	T2	20000411	JP 1998-520560	19971028
TW 445264	B	20010711	TW 1997-86115979	19971028
NO 9902066	A	19990629	NO 1999-2066	19990429
KR 2000052921	A	20000825	KR 1999-703789	19990429
PRIORITY APPLN. INFO.:			US 1996-741083 A	19961030
			WO 1997-US18986 W	19971028

OTHER SOURCE(S): MARPAT 129:4660

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9818788	A1	19980507	WO 1997-US18986	19971028
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
ZA 9709670	A	19980428	ZA 1997-9670	19971028
AU 9749917	A1	19980522	AU 1997-49917	19971028
AU 733454	B2	20010517		
EP 937069	A1	19990825	EP 1997-912827	19971028
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
BR 9712720	A	19991026	BR 1997-12720	19971028
CN 1241187	A	20000112	CN 1997-180916	19971028
JP 2000504342	T2	20000411	JP 1998-520560	19971028
TW 445264	B	20010711	TW 1997-86115979	19971028

09857869

NO 9902066            A        19990629            NO 1999-2066        19990429  
KR 2000052921        A        20000825            KR 1999-703789     19990429


IT 207404-51-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of diacylpiperazine derivs. as neurokinin antagonists)

RN 207404-51-1 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[3-[(2R)-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 207404-51-1P 207404-52-2P 207404-53-3P  
207404-54-4P 207404-55-5P 207404-56-6P  
207404-57-7P 207404-58-8P 207404-59-9P  
207404-60-2P 207404-61-3P 207404-62-4P  
207404-63-5P 207404-64-6P 207404-65-7P  
207404-66-8P 207404-67-9P 207404-68-0P  
207404-69-1P 207404-70-4P 207404-71-5P  
207404-72-6P 207404-73-7P 207404-93-1P  
207404-94-2P 207404-95-3P 207404-96-4P  
207404-97-5P 207404-98-6P 207404-99-7P  
207405-00-3P 207405-01-4P 207405-02-5P  
207405-03-6P 207405-04-7P 207405-05-8P  
207405-06-9P 207405-07-0P 207405-08-1P  
207405-09-2P 207405-10-5P 207405-11-6P  
207405-12-7P 207405-13-8P 207405-14-9P  
207405-15-0P 207405-16-1P 207405-17-2P  
207405-18-3P 207405-19-4P 207405-37-6P  
207405-45-6P 207405-46-7P 207405-47-8P  
207405-48-9P 207405-49-0P 207405-50-3P  
207405-51-4P 207405-52-5P 207405-53-6P  
207405-54-7P 207405-55-8P 207405-56-9P  
207405-72-9P 207405-73-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of diacylpiperazine derivs. as neurokinin antagonists)

IT 207564-69-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of diacylpiperazine derivs. as neurokinin antagonists)

09857869

09857869

L4 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:163574 CAPLUS

DOCUMENT NUMBER: 128:230391

TITLE: Preparation of N-(piperidinoacetyl)piperazines and analogs as neurokinin antagonists

INVENTOR(S): Shue, Ho-Jane; Shih, Neng-Yang; Blythin, David J.; Chen, Xiao; Piwinski, John J.; McCormick, Kevin D.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808826	A1	19980305	WO 1997-US14709	19970828
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5892039	A	19990406	US 1996-706016	19960830
AU 9740800	A1	19980319	AU 1997-40800	19970828
EP 927170	A1	19990707	EP 1997-938490	19970828
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
JP 2000516956	T2	20001219	JP 1998-511732	19970828

PRIORITY APPLN. INFO.:

US 1996-706016	A	19960830
WO 1996-US5660	W	19960501
US 1996-663880	A2	19960614
WO 1997-US14709	A	19970828

OTHER SOURCE(S): MARPAT 128:230391


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9808826	A1	19980305	WO 1997-US14709	19970828
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5892039	A	19990406	US 1996-706016	19960830
AU 9740800	A1	19980319	AU 1997-40800	19970828
EP 927170	A1	19990707	EP 1997-938490	19970828
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
JP 2000516956	T2	20001219	JP 1998-511732	19970828

IT 204058-53-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of N-(piperidinoacetyl)piperazines and analogs as neurokinin antagonists)

RN 204058-53-7 CAPLUS

CN Piperazine, 4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)-1-[(4-hydroxy-4-phenyl-1-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)



IT 204058-53-7P 204058-54-8P 204058-55-9P  
 204058-56-0P 204058-57-1P 204058-58-2P  
 204058-59-3P 204058-60-6P 204058-61-7P  
 204058-62-8P 204058-63-9P 204058-64-0P  
 204058-65-1P 204058-66-2P 204058-67-3P  
 204058-68-4P 204058-69-5P 204058-74-2P  
 204058-75-3P 204058-76-4P 204058-77-5P  
 204058-78-6P 204058-79-7P 204058-80-0P  
 204058-81-1P 204058-82-2P 204058-83-3P  
 204058-84-4P 204058-85-5P 204058-86-6P  
 204058-87-7P 204058-88-8P 204058-89-9P  
 204058-90-2P 204058-91-3P 204058-92-4P  
 204058-93-5P 204058-94-6P 204058-95-7P  
 204058-96-8P 204058-97-9P 204058-98-0P  
 204058-99-1P 204059-00-7P 204059-01-8P  
 204059-02-9P 204059-03-0P 204059-04-1P  
 204059-05-2P 204059-06-3P 204059-07-4P  
 204059-08-5P 204059-09-6P 204059-10-9P  
 204059-11-0P 204059-12-1P 204059-13-2P  
 204059-14-3P 204059-15-4P 204059-16-5P  
 204059-17-6P 204059-18-7P 204059-19-8P  
 204059-20-1P 204059-21-2P 204059-22-3P  
 204059-23-4P 204059-24-5P 204059-25-6P  
 204059-26-7P 204059-27-8P 204059-28-9P  
 204059-29-0P 204059-35-8P 204059-36-9P  
 204059-37-0P 204059-38-1P 204059-39-2P  
 204059-40-5P 204059-41-6P 204059-42-7P  
 204059-43-8P 204059-44-9P 204059-45-0P  
 204059-46-1P 204059-47-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of N-(piperidinoacetyl)piperazines and analogs as neurokinin antagonists)



09857869

L4 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:805724 CAPLUS

DOCUMENT NUMBER: 128:48500

TITLE: Preparation of heterocyclic peptide derivatives as farnesylprotein transferase inhibitors and anticancer agents

INVENTOR(S): Heimbrook, David C.; Oliff, Allen I.; Stirdivant, Steven M.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Heimbrook, David C.; Oliff, Allen I.; Stirdivant, Steven M.

SOURCE: PCT Int. Appl., 260 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9745412	A1	19971204	WO 1997-US8992	19970527
W:		AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
AU 9732151	A1	19980105	AU 1997-32151	19970527
EP 934270	A1	19990811	EP 1997-927776	19970527
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI		
JP 2000508335	T2	20000704	JP 1997-542869	19970527
PRIORITY APPLN. INFO.:			US 1996-18679P	P 19960530
			GB 1996-12913	A 19960618
			WO 1997-US8992	W 19970527

OTHER SOURCE(S): MARPAT 128:48500

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9745412	A1	19971204	WO 1997-US8992	19970527
W:		AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
AU 9732151	A1	19980105	AU 1997-32151	19970527
EP 934270	A1	19990811	EP 1997-927776	19970527
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI		
JP 2000508335	T2	20000704	JP 1997-542869	19970527

IT 183498-91-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(prepn. of heterocyclic peptide derivs. as farnesylprotein transferase inhibitors and anticancer agents)

RN 183498-91-1 CAPLUS

CN Piperazine, 1-(1H-imidazol-4-ylmethyl)-4-(1-naphthalenylcarbonyl)-2-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869



IT **183498-91-1**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of heterocyclic peptide derivs. as farnesylprotein transferase inhibitors and anticancer agents)

09857869

L4 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:696611 CAPLUS

DOCUMENT NUMBER: 127:359110

TITLE: Preparation of transferase inhibitors for treating cancer

INVENTOR(S): Gibbs, Jackson B.; Kohl, Nancy E.; Oliff, Allen I.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Gibbs, Jackson B.; Kohl, Nancy E.; Oliff, Allen I.

SOURCE: PCT Int. Appl., 301 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9738664	A2	19971023	WO 1997-US6248	19970415
WO 9738664	A3	19971120		
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2251955	AA	19971023	CA 1997-2251955	19970415
AU 9728022	A1	19971107	AU 1997-28022	19970415
EP 952842	A2	19991103	EP 1997-922313	19970415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000513711	T2	20001017	JP 1997-537313	19970415
PRIORITY APPLN. INFO.: US 1996-15589P P 19960418				
GB 1996-11982 A 19960607				
WO 1997-US6248 W 19970415				

OTHER SOURCE(S): MARPAT 127:359110

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9738664	A2	19971023	WO 1997-US6248	19970415
WO 9738664	A3	19971120		
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2251955	AA	19971023	CA 1997-2251955	19970415
AU 9728022	A1	19971107	AU 1997-28022	19970415
EP 952842	A2	19991103	EP 1997-922313	19970415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000513711	T2	20001017	JP 1997-537313	19970415

IT 183498-91-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of transferase inhibitors for treating cancer)

RN 183498-91-1 CAPLUS

CN Piperazine, 1-(1H-imidazol-4-ylmethyl)-4-(1-naphthalenylcarbonyl)-2-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869



IT **183498-91-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of transferase inhibitors for treating cancer)

09857869

L4 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:672274 CAPLUS

DOCUMENT NUMBER: 127:331747

TITLE: Preparation of imidazole derivatives and  
imidazole-contg. peptide analogs and a method of  
treating cancer

INVENTOR(S): Heimbrook, David C.; Oliff, Allen I.; Stirdivant,  
Steven M.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Heimbrook, David C.; Oliff,  
Allen I.; Stirdivant, Steven M.

SOURCE: PCT Int. Appl., 313 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736587	A1	19971009	WO 1997-US5328	19970331
W:		AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
CA 2250232	AA	19971009	CA 1997-2250232	19970331
AU 9727221	A1	19971022	AU 1997-27221	19970331
AU 727939	B2	20010104		
EP 906099	A1	19990407	EP 1997-921085	19970331
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI		
JP 2000504023	T2	20000404	JP 1997-535542	19970331
PRIORITY APPLN. INFO.:			US 1996-14773P	P 19960403
			GB 1996-13599	A 19960628
			WO 1997-US5328	W 19970331

OTHER SOURCE(S): MARPAT 127:331747

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9736587	A1	19971009	WO 1997-US5328	19970331
W:		AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
CA 2250232	AA	19971009	CA 1997-2250232	19970331
AU 9727221	A1	19971022	AU 1997-27221	19970331
AU 727939	B2	20010104		
EP 906099	A1	19990407	EP 1997-921085	19970331
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI		
JP 2000504023	T2	20000404	JP 1997-535542	19970331

IT 183498-91-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of imidazole derivs. as Raf protein antagonists and  
imidazole-contg. peptide analogs as farnesyl protein transferase  
inhibitors for treating cancer)


RN 183498-91-1 CAPLUS

CN Piperazine, 1-(1H-imidazol-4-ylmethyl)-4-(1-naphthalenylcarbonyl)-2-

09857869

(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **183498-91-1P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of imidazole derivs. as Raf protein antagonists and imidazole-contg. peptide analogs as farnesyl protein transferase inhibitors for treating cancer)

09857869

L4 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:502963 CAPLUS

DOCUMENT NUMBER: 127:121754

TITLE: Piperazine derivatives as tachykinin antagonists

INVENTOR(S): Matsuo, Masaaki; Manabe, Takashi; Konishi, Nobukiyo; Take, Kazuhiko; Igari, Norihiro; Shigenaga, Shinji; Matsuda, Hiroshi; Terasaka, Tadashi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Matsuo, Masaaki; Manabe, Takashi; Konishi, Nobukiyo; Take, Kazuhiko; Igari, Norihiro; Shigenaga, Shinji; Matsuda, Hiroshi; Terasaka, Tadashi

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9722597	A1	19970626	WO 1996-JP3641	19961212
<del>W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</del>				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9610428	A	19970624	ZA 1996-10428	19961211
CA 2240835	AA	19970626	CA 1996-2240835	19961212
AU 9711106	A1	19970714	AU 1997-11106	19961212
AU 714931	B2	20000113		
EP 873320	A1	19981028	EP 1996-941859	19961212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1209125	A	19990224	CN 1996-199963	19961212
JP 2000502100	T2	20000222	JP 1997-522654	19961212
US 6087357	A	20000711	US 1998-91269	19980618
US 2002010182	A1	20020124	US 2001-899942	20010709
PRIORITY APPLN. INFO.:				
			GB 1995-25841	A 19951218
			AU 1996-9891	A 19960516
			AU 1996-2683	A 19960930
			WO 1996-JP3641	W 19961212
			US 2000-545614	A1 20000406

OTHER SOURCE(S): MARPAT 127:121754


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9722597	A1	19970626	WO 1996-JP3641	19961212
W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9610428	A	19970624	ZA 1996-10428	19961211
CA 2240835	AA	19970626	CA 1996-2240835	19961212
AU 9711106	A1	19970714	AU 1997-11106	19961212
AU 714931	B2	20000113		
EP 873320	A1	19981028	EP 1996-941859	19961212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1209125	A	19990224	CN 1996-199963	19961212
JP 2000502100	T2	20000222	JP 1997-522654	19961212
US 6087357	A	20000711	US 1998-91269	19980618
US 2002010182	A1	20020124	US 2001-899942	20010709

IT 192659-81-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazine derivs. as tachykinin antagonists)

09857869

*prov. only*




● 2 HCl

RN 192660-42-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-[2-(trifluoromethyl)-4-morpholinyl]-2-butynyl]-, dihydrochloride, [4(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


RN 192660-44-9 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(3,3-dimethyl-4-morpholinyl)-2-butynyl]-2-[(3,4-dimethylphenyl)methyl]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



09857869




● 2 HCl

RN 192660-46-1 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-[2-(methoxymethyl)-1-pyrrolidinyl]-2-butynyl]-, dihydrochloride, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 192660-48-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-[3-(methoxymethyl)-4-morpholinyl]-2-butynyl]-, dihydrochloride, [4(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




●2 HCl

RN 192660-49-4 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[3-(3-pyridinyl)-2-propynyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



~~extended~~

●2 HCl


RN 192660-51-8 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(2-naphthalenylmethyl)-4-[4-(4-thiomorpholinyl)-2-butenyl]-, dihydrochloride, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

09857869




● 2 HCl

RN 192660-52-9 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(4-morpholinyl)-2-butenyl]-2-(2-naphthalenylmethyl)-, dihydrochloride, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




● 2 HCl

RN 192660-53-0 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-(4-thiomorpholinyl)-2-butenyl]-, dihydrochloride, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

09857869




●2 HCl

RN 192660-54-1 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(3,3-dimethyl-4-morpholinyl)-2-butenyl]-2-[(3,4-dimethylphenyl)methyl]-, dihydrochloride, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




●2 HCl

RN 192660-60-9 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[2-(1H-imidazol-1-yl)ethyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● 2 HCl

RN 192660-63-2 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[2-(tetrahydro-1,4-oxazepin-4(5H)-yl)ethyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 192660-64-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09857869



RN 192660-66-5 CAPLUS

CN Piperazine, 4-[3-(4-acetyl-1-piperidinyl)propyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 192660-67-6 CAPLUS

CN Piperazine, 4-[3-(4-acetyl-1-piperidinyl)propyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




●2 HCl

RN 192660-68-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-[2-(4-morpholinyl)ethyl]-, dihydrochloride, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 192660-71-2 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[3-(hexahydro-1H-azepin-1-yl)propyl]-, dihydrochloride, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● 2 HCl

RN 192660-74-5 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(2-naphthalenylmethyl)-4-[4-(4-thiomorpholinyl)-2-butynyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


RN 192660-75-6 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(4-cyclohexyl-1-piperazinyl)-2-butynyl]-2-[(3,4-dimethylphenyl)methyl]-, trihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09857869



● 3 HCl

RN 192660-76-7 CAPLUS  
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-(2-pyridinylmethyl)-, dihydrochloride, (R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 192660-78-9 CAPLUS  
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-(4-morpholinyl)-2-butenyl]-, dihydrochloride, [R-(Z)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

09857869




● 2 HCl

RN 192660-80-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[5-(4-morpholinyl)pentyl]-, dihydrochloride, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 192660-81-4 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-(4-morpholinyl)-2-butenyl]-, dihydrochloride, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

09857869

RN 192659-81-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[3-(4-thiomorpholinyl)propyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 192659-81-7P 192659-93-1P 192659-94-2P  
192659-96-4P 192659-97-5P 192659-99-7P  
192660-02-9P 192660-09-6P 192660-10-9P  
192660-11-0P 192660-13-2P 192660-14-3P  
192660-26-7P 192660-27-8P 192660-28-9P  
192660-29-0P 192660-32-5P 192660-33-6P  
192660-34-7P 192660-36-9P 192660-38-1P  
192660-40-5P 192660-42-7P 192660-44-9P  
192660-46-1P 192660-48-3P 192660-49-4P  
192660-51-8P 192660-52-9P 192660-53-0P  
192660-54-1P 192660-60-9P 192660-63-2P  
192660-64-3P 192660-66-5P 192660-67-6P  
192660-68-7P 192660-71-2P 192660-74-5P  
192660-75-6P 192660-76-7P 192660-78-9P  
192660-80-3P 192660-81-4P 192660-89-2P  
192661-02-2P 192661-03-3P 192661-05-5P  
192661-06-6P 192661-07-7P 192661-08-8P  
192661-09-9P 192661-11-3P 192661-12-4P  
192661-13-5P 192661-15-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazine derivs. as tachykinin antagonists)

IT 192661-46-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(starting material; prepn. of piperazine derivs. as tachykinin antagonists)

09857869

d 14 21 hitstr

L4 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2002 ACS


IT 192659-81-7P 192659-93-1P 192659-94-2P  
192659-96-4P 192659-97-5P 192659-99-7P  
192660-02-9P 192660-09-6P 192660-10-9P  
192660-11-0P 192660-13-2P 192660-14-3P  
192660-26-7P 192660-27-8P 192660-28-9P  
192660-29-0P 192660-32-5P 192660-33-6P  
192660-34-7P 192660-36-9P 192660-38-1P  
192660-40-5P 192660-42-7P 192660-44-9P  
192660-46-1P 192660-48-3P 192660-49-4P  
192660-51-8P 192660-52-9P 192660-53-0P  
192660-54-1P 192660-60-9P 192660-63-2P  
192660-64-3P 192660-66-5P 192660-67-6P  
192660-68-7P 192660-71-2P 192660-74-5P  
192660-75-6P 192660-76-7P 192660-78-9P  
192660-80-3P 192660-81-4P 192660-89-2P  
192661-02-2P 192661-03-3P 192661-05-5P  
192661-06-6P 192661-07-7P 192661-08-8P  
192661-09-9P 192661-11-3P 192661-12-4P  
192661-13-5P 192661-15-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazine derivs. as tachykinin antagonists)

RN 192659-81-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[3-(4-thiomorpholinyl)propyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 192659-93-1 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(4-morpholinyl)-2-butynyl]-2-(2-naphthalenylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09857869



●2 HCl

RN 192659-94-2 CAPLUS  
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-[4-(4-morpholinyl)-2-butynyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 192659-96-4 CAPLUS  
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-(4-morpholinyl)-2-butynyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● 2 HCl

RN 192659-97-5 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-(4-thiomorpholinyl)-2-butynyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 192659-99-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[2-(4-morpholinyl)ethyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




●2 HCl

RN 192660-02-9 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[2-(4-thiomorpholinyl)ethyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 192660-09-6 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(2-naphthalenylmethyl)-4-[3-(4-thiomorpholinyl)propyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09857869



RN 192660-10-9 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-(4-morpholinyl)ethyl]-2-(2-naphthalenylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192660-11-0 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(2-naphthalenylmethyl)-4-[2-(4-thiomorpholinyl)ethyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09857869




●2 HCl

RN 192660-13-2 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-[3-(4-thiomorpholinyl)propyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 192660-14-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-[3-(4-morpholinyl)propyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● 2 HCl

RN 192660-26-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[(1-methyl-1H-pyrazol-4-yl)methyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 192660-27-8 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[(1-methyl-1H-imidazol-4-yl)methyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




●2 HCl

RN 192660-28-9 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[(1-methyl-1H-imidazol-2-yl)methyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 192660-29-0 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[3-(4-morpholinyl)propyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● 2 HCl

RN 192660-32-5 CAPLUS

CN Piperazine, 4-[3-(3-azabicyclo[3.2.2]non-3-yl)propyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 192660-33-6 CAPLUS

CN Piperazine, 4-(3-[1,4'-bipiperidin]-1'-ylpropyl)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-, trihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09857869



●3 HCl

RN 192660-34-7 CAPLUS  
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-(4-morpholinyl)butyl]-, dihydrochloride, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 192660-36-9 CAPLUS  
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[5-(4-morpholinyl)-3-pentynyl]-, dihydrochloride, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● 2 HCl

RN 192660-38-1 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-(3-methyl-4-morpholinyl)-2-butynyl]-, dihydrochloride, [4(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 192660-40-5 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-[2-(methoxymethyl)-4-morpholinyl]-2-butynyl]-, dihydrochloride, [4(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● 2 HCl

RN 192660-89-2 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(2,6-dimethyl-4-morpholinyl)propyl]-2-[(3,4-dimethylphenyl)methyl]-, dihydrochloride, [4(R)-cis]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


RN 192661-02-2 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(2-naphthalenylmethyl)-4-[4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-2-butynyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

excluded  
but  
close to  
specimens 1,4

09857869




●2 HCl

RN 192661-03-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3-fluoro-4-methylphenyl)methyl]-4-[4-(4-morpholinyl)-2-butenyl]-, dihydrochloride, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



●2 HCl


RN 192661-05-5 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-fluorophenyl)methyl]-4-[4-(4-thiomorpholinyl)-2-butenyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09857869




● 2 HCl

RN 192661-06-6 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-methoxyphenyl)methyl]-4-[4-(4-thiomorpholinyl)-2-butynyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 192661-07-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(4-thiomorpholinyl)-2-butynyl]-2-[[4-(trifluoromethyl)phenyl]methyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




●2 HCl

RN 192661-08-8 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1-naphthalenylmethyl)-4-[4-(4-thiomorpholinyl)-2-butynyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 192661-09-9 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[3-(1-methyl-1H-pyrazol-4-yl)propyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● 2 HCl

RN 192661-11-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[3-(3-pyridinyl)propyl]-, dihydrochloride, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 192661-12-4 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(4-morpholinyl)-2-butynyl]-2-(2-naphthalenylmethyl)-, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


09857869



RN 192661-13-5 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-(4-morpholinyl)-2-butenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192661-15-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[4-(4-morpholinyl)-2-butenyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

09857869



IT 192661-46-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; prepn. of piperazine derivs. as tachykinin antagonists)

RN 192661-46-4 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[5-(4-morpholinyl)-3-pentynyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>

09857869

L4 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:80507 CAPLUS

DOCUMENT NUMBER: 126:104103

TITLE: 1-Benzoyl-2-(3-indolylalkyl)piperazine derivatives as neurokinin receptor antagonists

INVENTOR(S): Matsuo, Masaaki; Hagiwara, Daijiro; Manabe, Takashi; Konishi, Nobukiyo; Shigenaga, Shinji; Murano, Kenji; Matsuda, Hiroshi; Miyake, Hiroshi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9637489	A1	19961128	WO 1996-JP1335	19960521
W: AU, CA, CN, HU, JP, KR, MX, NZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2222041	AA	19961128	CA 1996-2222041	19960521
AU 9657031	A1	19961211	AU 1996-57031	19960521
AU 706021	B2	19990603		
EP 846116	A1	19980610	EP 1996-915200	19960521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1191533	A	19980826	CN 1996-195744	19960521
CN 1072220	B	20011003		
JP 11505830	T2	19990525	JP 1996-535553	19960521
JP 3071829	B2	20000731		
ZA 9604101	A	19960729	ZA 1996-4101	19960522
IL 118369	A1	20000601	IL 1996-118369	19960522
TW 391960	B	20000601	TW 1996-85106105	19960523
US 5883098	A	19990316	US 1997-884039	19970627

PRIORITY APPLN. INFO.:

US 1995-450176	A	19950525
GB 1993-24479	A	19931129
GB 1994-2010	A	19940202
GB 1994-12708	A	19940624
US 1994-348176	A2	19941128
WO 1996-JP1335	W	19960521

OTHER SOURCE(S): MARPAT 126:104103

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9637489	A1	19961128	WO 1996-JP1335	19960521
W: AU, CA, CN, HU, JP, KR, MX, NZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2222041	AA	19961128	CA 1996-2222041	19960521
AU 9657031	A1	19961211	AU 1996-57031	19960521
AU 706021	B2	19990603		
EP 846116	A1	19980610	EP 1996-915200	19960521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1191533	A	19980826	CN 1996-195744	19960521
CN 1072220	B	20011003		
JP 11505830	T2	19990525	JP 1996-535553	19960521
JP 3071829	B2	20000731		
ZA 9604101	A	19960729	ZA 1996-4101	19960522
IL 118369	A1	20000601	IL 1996-118369	19960522
TW 391960	B	20000601	TW 1996-85106105	19960523
US 5883098	A	19990316	US 1997-884039	19970627

IT 169459-22-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)


09857869

(intermediate; prepn. of benzoyl(indolylalkyl)piperazine derivs. as neurokinin receptor antagonists)

RN 169459-22-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(3-pyridinylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 169459-22-7P 169459-26-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(intermediate; prepn. of benzoyl(indolylalkyl)piperazine derivs. as neurokinin receptor antagonists)

09857869

=> d 14 22 hitstr

L4 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2002 ACS


IT **169459-22-7P 169459-26-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(intermediate; prepn. of benzoyl(indolylalkyl)piperazine derivs. as  
neurokinin receptor antagonists)

RN 169459-22-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(3-pyridinylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 169459-26-1 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(1H-indol-3-ylacetyl)-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





09857869

L4 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:38766 CAPLUS

DOCUMENT NUMBER: 126:59974

TITLE: Preparation of 1-benzoyl-2-[(4-piperidinylamino)acetyl]piperazines and analogs as neurokinin antagonists

INVENTOR(S): Shue, Ho-Jane; Shih, Neng-Yang; Blythin, David J.; Chen, Xiao; Tom, Wing C.; Piwinski, John J.; McCormick, Kevin D.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9634864	A1	19961107	WO 1996-US5660	19960501
W:	AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5719156	A	19980217	US 1995-432739	19950502
CA 2218887	AA	19961107	CA 1996-2218887	19960501
AU 9657141	A1	19961121	AU 1996-57141	19960501
AU 705683	B2	19990527		
EP 823906	A1	19980218	EP 1996-915342	19960501
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
BR 9608245	A	19990504	BR 1996-8245	19960501
JP 11504921	T2	19990511	JP 1996-533355	19960501
CA 2228370	AA	19970306	CA 1996-2228370	19960829
WO 9708166	A1	19970306	WO 1996-IB1018	19960829
W:	AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9669979	A1	19970319	AU 1996-69979	19960829
AU 708834	B2	19990812		
EP 850236	A1	19980701	EP 1996-931188	19960829
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI			
JP 10511105	T2	19981027	JP 1996-510069	19960829
CN 1200120	A	19981125	CN 1996-197720	19960829
BR 9610277	A	19990706	BR 1996-10277	19960829
JP 2000344766	A2	20001212	JP 2000-153870	19960829
AT 202776	E	20010715	AT 1996-931188	19960829
ES 2158345	T3	20010901	ES 1996-931188	19960829
US 5892039	A	19990406	US 1996-706016	19960830
ZA 9701467	A	19970820	ZA 1997-1467	19970220
NO 9705028	A	19971230	NO 1997-5028	19971031
NO 9800848	A	19980430	NO 1998-848	19980227
US 5981520	A	19991109	US 1998-99221	19980617
PRIORITY APPLN. INFO.:			US 1995-432739 A	19950502

US 1995-3084P P 19950831  
 WO 1996-US5660 A 19960501  
 US 1996-663880 A 19960614  
 JP 1997-510069 A3 19960829  
 WO 1996-IB1018 W 19960829

## OTHER SOURCE(S): MARPAT 126:59974

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9634864	A1	19961107	WO 1996-US5660	19960501
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5719156	A	19980217	US 1995-432739	19950502
	CA 2218887	AA	19961107	CA 1996-2218887	19960501
	AU 9657141	A1	19961121	AU 1996-57141	19960501
	AU 705683	B2	19990527		
	EP 823906	A1	19980218	EP 1996-915342	19960501
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	BR 9608245	A	19990504	BR 1996-8245	19960501
	JP 11504921	T2	19990511	JP 1996-533355	19960501
	CA 2228370	AA	19970306	CA 1996-2228370	19960829
	WO 9708166	A1	19970306	WO 1996-IB1018	19960829
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9669979	A1	19970319	AU 1996-69979	19960829
	AU 708834	B2	19990812		
	EP 850236	A1	19980701	EP 1996-931188	19960829
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI				
	JP 10511105	T2	19981027	JP 1996-510069	19960829
	CN 1200120	A	19981125	CN 1996-197720	19960829
	BR 9610277	A	19990706	BR 1996-10277	19960829
	JP 2000344766	A2	20001212	JP 2000-153870	19960829
	AT 202776	E	20010715	AT 1996-931188	19960829
	ES 2158345	T3	20010901	ES 1996-931188	19960829
	US 5892039	A	19990406	US 1996-706016	19960830
	ZA 9701467	A	19970820	ZA 1997-1467	19970220
	NO 9705028	A	19971230	NO 1997-5028	19971031
	NO 9800848	A	19980430	NO 1998-848	19980227
	US 5981520	A	19991109	US 1998-99221	19980617


## IT 185108-16-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 1-benzoyl-2-[(4-piperidinylamino)acetyl]piperazines and analogs as neurokinin antagonists)

RN 185108-16-1 CAPLUS

CN Piperazine, 4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)-1-[[5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]acetyl]- (9CI) (CA INDEX NAME)

09857869



IT 185108-16-1P 185109-65-3P 185109-69-7P  
185109-72-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 1-benzoyl-2-[(4-piperidinylamino)acetyl]piperazines and analogs as neurokinin antagonists)

09857869

L4 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:724170 CAPLUS

DOCUMENT NUMBER: 126:8133

TITLE: Preparation of piperazine and homopiperazine inhibitors of farnesyl-protein transferase.

INVENTOR(S): Anthony, Neville J.; Ciccarone, Terrence M.; Gomez, Robert P.; Hutchinson, John H.; Williams, Theresa M.; Dinsmore, Christopher J.; Stokker, Gerald E.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9630343	A1	19961003	WO 1996-US4019	19960325
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, US, US, UZ, VN, AM, AZ, BY, KG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5856326	A	19990105	US 1996-600728	19960301
AU 9653223	A1	19961016	AU 1996-53223	19960325
AU 710672	B2	19990923		
EP 820445	A1	19980128	EP 1996-909851	19960325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
BR 9607953	A	19980714	BR 1996-7953	19960325
JP 10511098	T2	19981027	JP 1996-529559	19960325
JP 3043815	B2	20000522		
ZA 9602433	A	19961002	ZA 1996-2433	19960327
NO 9704457	A	19971128	NO 1997-4457	19970926
PRIORITY APPLN. INFO.:				
			US 1995-412829	A1 19950329
			US 1995-470690	A1 19950606
			US 1996-600728	A1 19960301
			WO 1996-US4019	W 19960325

OTHER SOURCE(S): MARPAT 126:8133

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9630343	A1	19961003	WO 1996-US4019	19960325
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, US, US, UZ, VN, AM, AZ, BY, KG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5856326	A	19990105	US 1996-600728	19960301
AU 9653223	A1	19961016	AU 1996-53223	19960325
AU 710672	B2	19990923		
EP 820445	A1	19980128	EP 1996-909851	19960325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
BR 9607953	A	19980714	BR 1996-7953	19960325
JP 10511098	T2	19981027	JP 1996-529559	19960325
JP 3043815	B2	20000522		

09857869

ZA 9602433	A	19961002	ZA 1996-2433	19960327
NO 9704457	A	19971128	NO 1997-4457	19970926


IT **183498-91-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazine and homopiperazine inhibitors of farnesyl-protein transferase)

RN 183498-91-1 CAPLUS

CN Piperazine, 1-(1H-imidazol-4-ylmethyl)-4-(1-naphthalenylcarbonyl)-2-(phenylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **183498-91-1P 183498-92-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of piperazine and homopiperazine inhibitors of farnesyl-protein transferase)

IT **183499-83-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of piperazine and homopiperazine inhibitors of farnesyl-protein transferase)

09857869

L4 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:884027 CAPLUS

DOCUMENT NUMBER: 123:286083

TITLE: Preparation of piperazine-derivative tachykinin antagonists

INVENTOR(S): Matsuo, Masaaki; Hagiwara, Daijiro; Manabe, Takashi; Nobukiyo, Konishi; Shigenaga, Shinji; Murano, Kenji; Matsuda, Hiroshi; Miyake, Hiroshi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 114 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

*provided*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 655442	A1	19950531	EP 1994-118542	19941125
EP 655442	B1	20010523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
ZA 9409228	A	19950801	ZA 1994-9228	19941121
IL 111730	A1	19981206	IL 1994-111730	19941122
CA 2136712	AA	19950530	CA 1994-2136712	19941125
AU 9479111	A1	19950608	AU 1994-79111	19941125
AU 689504	B2	19980402		
ES 2156588	T3	20010701	ES 1994-118542	19941125
TW 384287	B	20000311	TW 1994-83111021	19941126
CN 1107149	A	19950823	CN 1994-117822	19941128
CN 1041923	B	19990203		
JP 07242641	A2	19950919	JP 1994-293388	19941128
JP 3129123	B2	20010129		
HU 71348	A2	19951128	HU 1994-3414	19941128
US 5670505	A	19970923	US 1994-348176	19941128
BR 9500539	A	19951031	BR 1995-539	19950202
US 5883098	A	19990316	US 1997-884039	19970627

PRIORITY APPLN. INFO.:

GB 1993-24479	A	19931129
GB 1994-2010	A	19940202
GB 1994-12708	A	19940624
US 1994-348176	A2	19941128
US 1995-450176	B1	19950525

OTHER SOURCE(S): MARPAT 123:286083

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 655442	A1	19950531	EP 1994-118542	19941125
EP 655442	B1	20010523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
ZA 9409228	A	19950801	ZA 1994-9228	19941121
IL 111730	A1	19981206	IL 1994-111730	19941122
CA 2136712	AA	19950530	CA 1994-2136712	19941125
AU 9479111	A1	19950608	AU 1994-79111	19941125
AU 689504	B2	19980402		
ES 2156588	T3	20010701	ES 1994-118542	19941125
TW 384287	B	20000311	TW 1994-83111021	19941126
CN 1107149	A	19950823	CN 1994-117822	19941128
CN 1041923	B	19990203		
JP 07242641	A2	19950919	JP 1994-293388	19941128
JP 3129123	B2	20010129		
HU 71348	A2	19951128	HU 1994-3414	19941128
US 5670505	A	19970923	US 1994-348176	19941128
BR 9500539	A	19951031	BR 1995-539	19950202

09857869

US 5883098 A 19990316 US 1997-884039 19970627

IT 169459-14-7P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperazine-deriv. tachykinin antagonists)

RN 169459-14-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-(1H-indol-2-yl)ethyl]-2-(phenylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 169459-14-7P 169459-18-1P 169459-22-7P  
169459-26-1P 169459-35-2P 169459-36-3P  
169459-37-4P 169459-41-0P 169459-51-2P  
169459-52-3P 169459-56-7P 169459-57-8P  
169459-64-7P 169459-69-2P 169459-70-5P  
169459-71-6P 169459-86-3P 169460-03-1P  
169460-05-3P 169460-11-1P 169460-19-9P  
169460-30-4P 169460-31-5P 169460-32-6P  
169460-44-0P 169460-51-9P 169460-52-0P  
169460-99-5P 169461-00-1P 169461-01-2P  
169461-30-7P 169462-35-5P 169462-51-5P  
169462-64-0P 169462-78-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperazine-deriv. tachykinin antagonists)

09857869

> d 14 25 hitstr

L4 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2002 ACS

IT 169459-14-7P 169459-18-1P 169459-22-7P  
169459-26-1P 169459-35-2P 169459-36-3P  
169459-37-4P 169459-41-0P 169459-51-2P  
169459-52-3P 169459-56-7P 169459-57-8P  
169459-64-7P 169459-69-2P 169459-70-5P  
169459-71-6P 169459-86-3P 169460-03-1P  
169460-05-3P 169460-11-1P 169460-19-9P  
169460-30-4P 169460-31-5P 169460-32-6P  
169460-44-0P 169460-51-9P 169460-52-0P  
169460-99-5P 169461-00-1P 169461-01-2P  
169461-30-7P 169462-35-5P 169462-51-5P  
169462-64-0P 169462-78-6P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperazine-deriv. tachykinin antagonists)

RN 169459-14-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-(1H-indol-2-yl)ethyl]-2-(phenylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 169459-18-1 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(1H-indol-2-yl)propyl]-2-(phenylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09857869



● HCl

RN 169459-22-7 CAPLUS  
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(3-pyridinylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

must be substd

RN 169459-26-1 CAPLUS  
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(1H-indol-3-ylacetyl)-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169459-35-2 CAPLUS  
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(1H-indol-3-ylcarbonyl)-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09857869



RN 169459-36-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(1H-indol-3-yl)-1-oxopropyl]-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169459-37-4 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(1H-indol-3-yl)-1-oxobutyl]-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 169459-41-0 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(1H-indol-3-yl)-1-oxo-2-propenyl]-2-(phenylmethyl)-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

09857869




RN 169459-51-2 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-2-(phenylmethyl)-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 169459-52-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(3-furanyl)-1-oxo-2-propenyl]-2-(phenylmethyl)-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 169459-56-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[1-oxo-3-(3-thienyl)-2-propenyl]-2-(phenylmethyl)-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


09857869



RN 169459-57-8 CAPLUS

CN Acetamide, N-[4-[3-[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(phenylmethyl)-1-piperazinyl]-3-oxo-1-propenyl]-2-thiazolyl]-, [R-(E)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 169459-64-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 169459-69-2 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(3-pyridinylacetyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● HCl

RN 169459-70-5 CAPLUS

CN Piperazine, 4-(2-benzofuranylcarbonyl)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169459-71-6 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(3-pyridinylcarbonyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl


RN 169459-86-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-

09857869

dimethylphenyl)methyl]-4-(3-pyridinylcarbonyl)-, monohydrochloride, (R)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 169460-03-1 CAPLUS

CN Acetamide, N-[4-[3-[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]-3-oxo-1-propenyl]-2-thiazolyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 169460-05-3 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(1H-indol-3-ylmethyl)-2-(phenylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● HCl

RN 169460-11-1 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[(1-methyl-1H-indol-3-yl)methyl]-2-(phenylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 169460-19-9 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-, monohydrochloride, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

09857869




● HCl

RN 169460-30-4 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-2-[(3,4-dimethylphenyl)methyl]-, (R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 169460-31-5 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[2-oxo-2-(3-pyridinyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09857869




● HCl

RN 169460-32-6 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-2-[(3,4-dimethylphenyl)methyl]-, (R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 169460-44-0 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(2-thienyl)-2-propenyl]-, [R-(E)]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


09857869



RN 169460-51-9 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-(3-pyridinylacetyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 169460-52-0 CAPLUS

CN Piperazine, 1-(3,5-dimethylbenzoyl)-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


09857869



RN 169460-99-5 CAPLUS

CN Acetamide, N-[1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]acetyl]-4-phenyl-4-piperidinyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 169461-00-1 CAPLUS

CN Morpholine, 4-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]acetyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09857869




● HCl

RN 169461-01-2 CAPLUS

CN Acetamide, N-[1-[2-[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]-2-oxoethyl]-4-phenyl-4-piperidinyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-30-7 CAPLUS

CN Acetamide, N-[4-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]methyl]-2-thiazolyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Chemical structure of a substituted piperazine derivative. The structure features a piperazine ring with a 4-methylbenzyl group at position 2 (wedge bond) and a 4-(trifluoromethyl)benzoyl group at position 1 (dashed bond). The nitrogen at position 4 is substituted with a 1,3,4-oxadiazole ring. The 5-position of the oxadiazole ring is circled and labeled 'AcNH' with arrows pointing to the 4 and 5 positions, indicating a site for acetylation.


Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-, monohydrochloride, [S(E)]- (9CI) (CA INDEX NAME)

Chemical structure of compound 10: A piperazine ring substituted with a 4-methylbenzyl group, a 4-(trifluoromethyl)benzoyl group, and a 4-pyridylmethyl group via an E-alkene linker.

CN 1-Pyrrolidinecarboxylic acid, 2-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(phenylmethyl)-1-piperazinyl]carbonyl]-4-hydroxy-, 1,1-dimethylethyl ester, [2S-[2.alpha.(S\*),4.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09857869



RN 169462-64-0 CAPLUS

CN Piperazine, 4-[(2-amino-4-thiazolyl)methyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



102

●2 HCl


RN 169462-78-6 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-, [S-(E)]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

09857869



=>

09857869

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

84.66

481.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-15.49

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 16:32:42 ON 18 JUN 2002